Immunotherapies Show Promise in Small-Cell Lung Cancer

Video

This video reviews immunotherapy trials in small-cell lung cancer, including studies on pembrolizumab, nivolumab monotherapy, and nivolumab in combination with ipilimumab.

Immunotherapy has shown efficacy in lung cancer, with several drugs already approved for patients with non–small-cell lung cancer (anti–PD-1 agent nivolumab, anti–PD-L1 agents pembrolizumab and atezolizumab)‎.

In this video, Gregory P. Kalemkerian, MD, of the University of Michigan Health System, discusses immunotherapies in the small-cell lung cancer (SCLC) setting.

Kalemkerian reviews the results of several trials in SCLC, including nivolumab monotherapy or in combination with the CTLA-4 blocker ipilimumab, and pembrolizumab.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Related Content
THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

Gina Mauro
June 5th 2025
Article

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Benmelstobart With/Without Anlotinib Is Effective Consolidation Therapy in NSCLC

Benmelstobart With/Without Anlotinib Is Effective Consolidation Therapy in NSCLC

Jordyn Sava
June 3rd 2025
Article

Benmelstobart-based regimens provide clinically meaningful PFS benefits as consolidation therapy for unresectable stage III non–small cell lung cancer.

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

3 Things You Should Know About the Multimodal Treatment of SCLC

3 Things You Should Know About the Multimodal Treatment of SCLC

Lauren Averett Byers, MD;Percy Lee, MD, FASTRO;Erminia Massarelli, MD, PhD, MS
May 19th 2025
Article

Here are 3 things you should know about the multimodal treatment of patients with SCLC.

HITOCH After Surgery Appears Safe, May Improve Survival in Mesothelioma

HITOCH After Surgery Appears Safe, May Improve Survival in Mesothelioma

Tim Cortese
May 6th 2025
Article

A systematic review shows that patients with mesothelioma who received HITOCH experienced between 13 to 35 months of survival.